Complement-Mediated Enhancement of HIV-1 Infection in Peripheral Blood Mononuclear Cells

References

• Spear G T, Sullivan B L, Landay A L, Lint T F. Neutralization of human immunodeficiency virus type 1 by complement occurs by viral lysis. J Virol 1990; 64: 5869–73
   PubMedGoogle Scholar
• Marschang P, Sodroski J, Wurzner R, Dierich M P. Decay-accelerating factor (CD55) protects human immunodeficiency virus type 1 from inactivation by human complement. Eur J Immun 1995; 25: 285–90
   PubMed Web of Science ®Google Scholar
• Stoiber H, Pinter C, Siccardi A G, Clivio A, Dierich M P. Efficient destruction of human immunodeficiency virus in human serum by inhibiting the protective action of complement factor H and decay accelerating Factor (DAF, CD55). J Exp Med 1996; 183: 307–10
   PubMed Web of Science ®Google Scholar
• Robinson W E, Montefiori D C, Gillespie D H, Mitchell W M. Complement-mediated, antibody-dependent enhancement of HIV-1 infection in vitro is characterized by increased protein and RNA syntheses and infectious virus release. J Acq Imm Def Syn 1989; 2: 33–42
   PubMedGoogle Scholar
• Gras G S, Dormont D. Antibody-dependent and antibody independent complement mediated enhancement of human immunodeficiency virus type 1 infection in a human, Epstein–Barr virus-transformed B-tymphocytic cell line. J Virol 1991; 65: 541–5
   PubMedGoogle Scholar
• Thieblemont N, Delibrias C, Fischer E, Weiss L, Katatchkine M D, Haeffner-Cavaillon N. Complement enhancement of HIV infection is mediated by complement receptors. Immunopharmacology 1993; 25: 87–93
   PubMedGoogle Scholar
• Lund O, Hansen J, Sørensen A M, Mosekilde E, Nielsen J O, Hansen J ES. Increased adhesion as a mechanism of antibody-dependent and antibody-independent complement-mediated enhancement of human immunodeficiency virus infection. J Virol 1995; 69: 2393–400
   PubMedGoogle Scholar
• Tóth F D, Szabó B, Ujhelyi E, Pálóczi K, Horvárth A, Füst G. Neutralizing and complement dependent enhancing antibodies in different stages of HIV infection. AIDS 1991; 5: 263–8
   PubMed Web of Science ®Google Scholar
• Füst G, Toth F D, Kiss J, Ujhelyi E, Nagy I, Bánhegyi D. Neutralizing and enhancing antibodies measured in complement-restored serum samples from HIV-1-infected individuals correlate with immunosuppression and disease. AIDS 1994; 8: 603–9
   PubMedGoogle Scholar
• Montefiori D C, Graham B S, Kliks S, Wright P F. Serum antibodies to HIV-1 in recombinant vaccinia virus recipients boosted with purified recombinant gp160. J Clin Immun 1992; 12: 429–39
   PubMedGoogle Scholar
• Montefiori D C, Pantaleo G, Fink L M, Zhou J T, Zhou J Y, Bilska M, Miralles G D, Fauci A S. Neutralizing and infection-enhancing antibody responses to human immunodeficiency virus type 1 in long-term nonprogressors. J Inf Dis 1996; 173: 60–7
   PubMed Web of Science ®Google Scholar
• Mascola J R, Mathieson B J, Zack P M, Walker M C, Halstead S B, Burke D S. Summary report: Workshop on the potential risk of antibody-dependent enhancement in human HIV vaccine trials. AIDS Res Hum Retro 1993; 9: 1175–84
   PubMedGoogle Scholar
• Moore J P, Cao Y, Qing L, Sattentau Q J, Pyati J, Koduri R. Primary isolates of human immunodeficiency virus type 1 are relatively resistant to neutralization by monoclonal antibodies to gp120, and their neutralization is not predicted by studies with monomeric gp120. J Virol 1995; 69: 101–9
   PubMed Web of Science ®Google Scholar
• Robinson W E, Montefiori D C, Mitchell W M. Complement-mediated enhancement of HIV-1 infection requires CD4 and complement receptors. Virology 1990; 175: 600–4
   PubMed Web of Science ®Google Scholar
• Boyer V, Desgranges C, Trabaud M A, Fischer E, Kazatchkine M D. Complement mediates human immunodeficiency virus type 1 infection of a human T cell line in a CD4-and antibody-independent fashion. J Exp Med 1991; 173: 1151–8
   PubMed Web of Science ®Google Scholar
• Montefiori D C, Stewart K, Ahearn J M, Zhou J. Zhou JComplement-mediated binding of naturally glycosylated and glycosylation-modified human immunodeficiency virus type 1 to human CR2 (CD21). J Virol 1993; 67: 2699–706
   PubMedGoogle Scholar
• Fischer E, Delibrias C, Kazatchkine M D. Expression of CR2 (the C3dg/EBV receptor, CD21) on normal human peripheral blood T lymphocytes. J Immun 1991; 146: 865–9
   PubMed Web of Science ®Google Scholar
• June R A, Landay A L, Stefanik K, Lint T F, Spear G T. Phenotypic analysis of complement receptor 2+ T lymphocytes: reduced expression on CD4+ cells in HIV-infected persons. Immunology 1992; 75: 59–65
   PubMedGoogle Scholar
• Zack J A, Arrigo S J, Weitsman S R, Go A S, Haislip A. Chen ISY. HIV-1 entry into quiescent primary lymphocytes: molecular analysis reveals a labile, latent viral structure. Cell 1990; 61: 213–22
   PubMed Web of Science ®Google Scholar
• Zhang H, Dornadula G, Pomerantz R J. Endogenous reverse transcription of human immuno-deficiency virus type 1 in physiological microenvironments: an important stage for viral infection of nondividing cells. J Virol 1996; 70: 2809–24
   PubMed Web of Science ®Google Scholar
• Miltenyi S, Müller W, Weichel W, Radbruch A. High gradient magnetic cell separation with MACS. Cytometry 1990; 11: 231–8
   PubMedGoogle Scholar
• Nielsen S D, Nielsen J O, Hansen J ES. In vitro separation and expansion of CD4 lymphocytes from HIV-infected individuals without activation of HIV-infection. J Immun Meth 1997; 200: 107–12
   PubMedGoogle Scholar
• Schønning K, Nielsen C, Iversen J, Nielsen J O, Hansen J ES. Neutralizing antibodies in slowly progressing HIV-1 infection. J Acq Imm Def Syn 1995; 10: 400–7
   Google Scholar
• Gras G, Strub T, Dormont D. Antibody-dependent enhancement of HIV infection. Lancet 1988; i: 1285
   Google Scholar
• Wu S C, Spouge J L, Conley S R, Tsai W P, Merges M J, Nara P L. Human plasma enhances the infectivity of primary human immunodeficiency virus type 1 isolates in peripheral blood mononuclear cells and monocyte-derived macrophages. J Virol 1995; 69: 6054–62
   PubMedGoogle Scholar
• June R A, Schade S Z, Bankowski M J, Kuhns M, McNamara A, Lint A L. Complement and antibody mediate enhancement of HIV infection by increasing virus binding and provirus formation. AIDS 1991; 5: 269–74
   PubMedGoogle Scholar
• Sawyer L S, Wrin M T, Crawford-Miksza L, Potts B, Wu Y, Weber P A. Neutralization sensitivity of human immunodeficiency virus type 1 is determined in part by the cell in which the virus is propagated. J Virol 1994; 68: 1342–9
   PubMed Web of Science ®Google Scholar